ALEXION PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Lysosomal Acid Lipase (LAL) Deficiency Registry
- Conditions
- Cholesterol Ester Storage DiseaseWolman DiseaseAcid Lipase DeficiencyLysosomal Acid Lipase DeficiencyAcid Cholesteryl Ester Hydrolase Deficiency, Type 2LIPA DeficiencyLAL-Deficiency
- First Posted Date
- 2012-07-04
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 1000
- Registration Number
- NCT01633489
- Locations
- 🇪🇸
Hospital Regional Universitario de Málaga, Andalusia, Spain
🇪🇸Hospital Universitario Central de Asturias, Asturias, Spain
🇪🇸Hospital Clínico Universitario Santiago de Compostela, Galicia, Spain
Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor
- First Posted Date
- 2012-03-30
- Last Posted Date
- 2019-05-03
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT01567085
An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype
- Conditions
- Cholesterol Ester Storage Disease(CESD)Lysosomal Acid Lipase Deficiency
- First Posted Date
- 2012-02-08
- Last Posted Date
- 2016-07-20
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT01528917
- Locations
- 🇺🇸
Morgan Stanley Children's Hospital of New York-Presbyterian, New York, New York, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
aHUS Observational Long Term Follow-Up
- Conditions
- Atypical Hemolytic Uremic Syndrome
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 94
- Registration Number
- NCT01522170
- Locations
- 🇺🇸
Emory Healthcare - Children's Center, Atlanta, Georgia, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Dunwoody Pediatrics & Children's Healthcare of Atlanta, Dunwoody, Georgia, United States
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
- Conditions
- Atypical Hemolytic-Uremic Syndrome
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 3000
- Registration Number
- NCT01522183
- Locations
- 🇬🇧
Clinical Trial Site, Wales, United Kingdom
🇪🇸Clinical Trial Site 1, Barcelona, Spain
🇪🇸Clinical Trial Site 2, Barcelona, Spain
Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency
- Conditions
- LAL-DeficiencyCholesterol Ester Storage Disease (CESD)Lysosomal Acid Lipase Deficiency
- Interventions
- First Posted Date
- 2011-12-08
- Last Posted Date
- 2018-07-20
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT01488097
Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects
- First Posted Date
- 2011-10-19
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT01454986
- Locations
- 🇺🇸
PAREXEL Baltimore EPCU, Baltimore, Maryland, United States
A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
- Conditions
- Hypophosphatasia (HPP)
- First Posted Date
- 2011-08-17
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT01419028
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Indiana University school of medicine, Indianapolis, Indiana, United States
🇺🇸Shriners Hospital for Children, Saint Louis, Missouri, United States
Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study
- Conditions
- PNHParoxysmal Nocturnal Hemoglobinuria
- First Posted Date
- 2011-08-08
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT01412047
- Locations
- 🇩🇪
Universitatsklinikum Essen, Essen, Germany
🇩🇪Institut fur Klinische Transfusionmedizin und Immungenetick, Ulm, Germany
🇮🇹Azienda Ospediliera Universitatia Careggi, Firenze, Italy
Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)
- Conditions
- Shiga-like Toxin-producing Escherichia Coli
- First Posted Date
- 2011-08-05
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 198
- Registration Number
- NCT01410916